Submitted for Publication: September 11, 2012; final revision received December 2, 2012; accepted January 21, 2013.
Published Online: August 21, 2013. doi:10.1001/jamapsychiatry.2013.2053.
Study concept and design: All authors.
Acquisition of data: Bobo, Cooper, Daugherty, Ray.
Analysis and interpretation of data: Bobo, Cooper, Stein, Olfson, Graham, Ray.
Drafting of the manuscript: Bobo, Ray.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Graham, Ray.
Obtained funding: Ray.
Administrative, technical, or material support: Cooper, Daugherty.
Study supervision: Cooper, Ray.
Conflict of Interest Disclosures: Dr Bobo has received research support from Cephalon and served on speaker bureaus for Janssen Pharmaceutica and Pfizer. Dr Olfson has received support from a research grant to Columbia University from Eli Lilly (end date June 20, 2010) and one from Bristol-Myers Squibb (end date January 31, 2010). No other disclosures are reported.
Funding/Support: This study was supported by the Agency for Healthcare Research and Quality, Centers for Education and Research on Therapeutics cooperative agreement (grant HS1-16974).
Disclaimer: The views expressed are solely the responsibility of the authors and do not necessarily represent the official views of the US Food and Drug Administration.
Additional Information: The first draft of the article was written by Drs Bobo and Ray, who vouch for the data and the analysis.
Additional Contributions: We gratefully acknowledge the Tennessee Bureau of Medicaid and the Department of Health, which provided study data.